Business
OXB to participate in investor conferences
Oxford Biomedica PLC (OXB) announced that senior management will participate in upcoming investor conferences and events. These include the Stifel Healthcare Conference in New York on November 11, 2025, with a fireside chat at 13:20 ET/18:20 GMT, and the Jefferies Global Healthcare Conference in London on November 18, 2025, featuring a presentation at 11:30 GMT/06:30 ET. Additionally, they will participate in the Jefferies C-Suite "Back to School" Fireside Chat virtually on November 4, 2025. Live webcasts and recordings of presentations, where available, will be accessible on OXB's website. Disclaimer*
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n\n \n \n \nOXB to participate in upcoming investor conferences and events\n \nOxford, UK - 27 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial Officer, will participate in the following upcoming investor conferences and events. Details are provided below.\n \n \nConferences\n \nStifel Healthcare Conference (New York)\n· Date: 11 November 2025\n· Fireside chat: 13:20 ET / 18:20 GMT\n \nJefferies Global Healthcare Conference (London)\n· Date: 18 November 2025\n· Presentation: 11:30 GMT / 06:30 ET\n \nEvents\n \nJefferies C-Suite \"Back to School\" Fireside Chat (Virtual)\n· Date: 4 November 2025\n \n \nLive webcasts and recordings of presentations, where available, will be accessible under 'Results, Reports, Presentations & Webcasts' in the Investor Relations section of OXB's website at www.oxb.com.\n \nFor details of other upcoming financial events, please refer to the Company's investor calendar at https://oxb.com/investor-events/. \n \n-Ends-\n \nEnquiries: \n \nOXB:\nT: +44 (0) 1865 509 737 / E: [email protected]\nSophia Bolhassan, Head of Investor Relations\nICR Healthcare:\nT: +44 (0)20 3709 5700 / E: [email protected]\nMary-Jane Elliott / Angela Gray / Davide Salvi\n \n \nAbout OXB\n \nOXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.\n \nOne of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral v...